Schizophrenia Treatment Flashcards

(57 cards)

1
Q

DSM-5 Criteria for Schizophrenia

A
	2 or more of the following persisting for at least 1 month:  At least one of the symptoms must be (1), (2), or (3): 
•	Delusions
•	Hallucinations
•	Disorganized Speech
•	Disorganized or catatonic behavior
•	Negative symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Other things to look for when diagnosis Schizo

A

 Level of social and/or occupational functioning has significantly declined
 Continuous signs for at least 6 months. May include prodromal or residual symptoms
 Schizoaffective or mood disorder has been excluded
 Disorder not due to a medical disorder or substance abuse
 If a development disorder is present, there must be symptoms of hallucinations/delusions for at least 1 month

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Acute Stabilization Treatment

A

Initiate antipsychotic treatment and titrate the dose every few days
If “cheeking” use liquid or orally disintegrating tablets
For severely agitate patients, consider quick actin antipsychotic by IM injection
Chemical restraining is recommended over physical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

During the first 7 days pf acute stabilization, you should see:

A

decreased agitation, hostility, anxiety, and aggression & sleep and appetite should improve

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Define cheeking

A

When a patient appears to be taking his medication, but instead places the pill inside of his cheek and spit sit out when no one is looking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Stabilization Treatment

A

Takes 6 weeks or longer
 If no improvement is seen within 3-4 weeks or only a partial decrease in positive symptoms is observed within 12 weeks with therapeutic doses then the next treatment algorithm stage should be considered.
 Continue increasing the antipsychotic dose gradually for more symptom control if tolerated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Goal of treatment:

A

Achieve no or minimal positive symptoms

Negative/cognitive symptoms are less likely to remit even with appropriate treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Maintenance Treatment

A

Continued treatment with antipsychotic therapy is recommended to prevent future relapses
At least 5 years but lifetime for chronically ill

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

For patients experiencing their first psychotic episode –

A

A first or second generation antipsychotic other than clozapine or olanzapine is recommended.
• If the first agent is not effective, then switch to another first or second generation antipsychotic other than clozapine. Olanzapine can be considered as an option at this stage.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

For patients who have experienced more than 1 psychotic episode but they have been treatment responsive in the past-

A
  • A first or second generation antipsychotic other than clozapine is recommended.
  • If the first agent is not effective, then switch to another first or second generation antipsychotic other than clozapine.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

For treatment resistant patients

A
  • Clozapine is the recommended antipsychotic for treatment resistant patients.
  • Clozapine can be offered sooner for patients with violent behaviors or suicidality.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Define Treatment Resistant

A

Failing 2 or more antipsychotic trials where the antipsychotic were dosed appropriately and given for an appropriate amount of time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

***Class 1 Antipsychotics

A
Chlorpromazine 
Thioridazine 
Loxapine 
Perphenazine 
Thiothixene 
Haloperidol 
Fluphenazine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Chlorpromazine and Thioridazine have

A

low EPS and high metabolic side effects (anti-cholinergic, sedation/weight gain, low BP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Loxapine, perphenazine, thiothixene, haloperidol and fluphenazine all have

A

HIGH EPS but low metabolic side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

2nd Generation Antipsychotics

A
THE “PINES” 
Clozapine
Olanzapine
Quetiapine
Asenapine 
THE “DONES”
Risperidone
Paliperidone
Ziprasidone 
Iloperidone 
Lurasidone
THE D2 PARTIAL AGONISTS
(THE “PIPS”)
Aripiprazole
Brexpiprazole
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

The Pines all show

A

Low EPS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Ziprasidone shows

A

Low side effects overall

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Illoperidone shows

A

Low EPS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Risperidone, Paliperidone, Lurasidone show

A

High EPS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

The PIPs show

A

Low everything but Aripiprazole has akathisia while brexpiprazole does not

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Weight Monitoring

A

Baseline then every month for 3 months and then every 3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Waist Circumference Monitoring

A

Baseline and annually

24
Q

Blood pressure and FPG monitoring

A

Baseline then 12 weeks then annually

25
FLP Monitoring
Baseline then 12 weeks then every 1-5 years
26
Clozapine Counseling and Monitoring
o May take daily dose once daily at bedtime or may divide dose into BID dosing o Dose must be started low and titrated gradually to avoid orthostatic hypotension. If doses are missed > 3 days then the patient needs to restart the dosing titration o If patient becomes neutropenic (ANC
27
Define Parkinsonism
* Patient may experience muscle rigidity, tremor, bradykinesia, and postural instability * 1-2 weeks after the antipsychotic is started or after a dose increase
28
Treatment of Parkinsonism
Anticholinergics (benztropin, diphenhydramine, trihexphenidyl)
29
Define Dystonia
Dystonia is tonic muscle contractions. These contractions often occur in the neck and shoulder muscles • 1-4 days after the antipsychotic is started or after a dose increase.
30
Dystonia Treatment
Anticholinergics
31
Akathisia
Akathisia is a constant feeling of inner restlessness. The patient may pace back and forth, shift constantly in their seat, seen tapping their feet
32
Treatment of Akathisia
It is recommended to reduce the antipsychotic dose or use a different agent. Propranolol may be effective in reducing akathisia in some patients
33
Define Tardive Dyskinesia
• Tardive dyskinesia is involuntary movements of the muscles. Usually the facial muscles are affected (sticking out tongue, puckering lips, lip smacking, grimacing) but it can also be observed in the extremities and truncal area in severe cases
34
Treatment of Tardive Dyskinesia
Recommended to decrease and/or discontinue the antipsychotic and switch to an agent that has less dopamine antagonism. Symptoms will appear to worsen at first, followed by slow improvement
35
Define AIMS
Abnormal Involuntary Movement Scale  Clinicians should administer the scale at baseline before a new antipsychotic is started and every 3-6 months after  Observing any abnormal movements
36
Haloperidol
First Generation Antipsychotics 1A2 Monitor: EKG Counsel: May take daily dose once at bedtime or divide into BID
37
Fluphenazine
First Generation Antipsychotics 2D6 Monitor: EKG, CBC, BP Counsel: May take daily dose once at bedtime or divide into BID
38
Perphenazine
First Generation Antipsychotics 2D6 Monitor: EKG, CBC, BP Counsel: BID or TID
39
Loxapine
First Generation Antipsychotics 1A2 Monitor: EKG, BP Counsel: May take daily dose once at bedtime or divide into BID
40
Clozapine
Second Generation 1A2 Monitor: HR, BP, Constipation Counsel: May take daily dose once at bedtime or divide into BID
41
Olanzapine
Second generation 1A2 Monitor: CBC and metabolic Counsel: QHS
42
Risperidone
Second generation 2D6 Monitor: BP and metabolic Counsel: May take daily dose once at bedtime or divide into BID
43
Paliperidone
Second generation No CYP Monitor: BP and metabolic Counsel: QHS
44
Quetiapine
Second Generation 3A4 Monitor: BP and metabolic Counsel: ER- QHS, IR- BID to TID
45
Ziprasidone
Second Generation 3A4 Monitor: EKG Counsel: BID, take with 500 calorie meal
46
Aripiprazole
Second generation 2D6 and 3A4 Monitor: AIMS only Counsel: QAM
47
Iloperidone
Second generation 3A4 and 2D6 Monitor: BP, EKG, metabolic Counsel: BID
48
Asenapine
Second Generation 1A2 Monitor: EKG and metabolic Counsel: BID sublingual
49
Lurasidone
Second generation 3A4 Monitor: AIMS only Counsel: QD with evening 500 calorie meal
50
Brexipirazole
``` Second generation 3A4 and 2D6 Monitor: AIMS only COunsel QAM ```
51
Aripiprazole IM
Abilify Maintena | 400 mg → given once monthly – 14 day overlap
52
Haloperidol IM
Haldol D | 10-15 X → given once monthly – 1 month overlap
53
Paliperidone IM
Invega Sustenna | 234 mg → 156 mg → given once monthly – no overlap
54
Olanzapine IM
Zyprexa Relprevv | Q2 wks x 4 doses → given once/twice monthly – none listed
55
Risperidone IM
Risperdal Consta | given every 2 weeks – 3 week overlap
56
Fluphenazine IM
Prolixin D | 1.2 X → given weekly for 4-6 wks then every 3-6 weeks- 1 week overlap
57
CATIE/CUtLASS Study
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study and the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS) showed no difference between second generation and first generation antipsychotics when comparing clinical outcomes such as time to discontinuation and quality of life. Both studies were federally funded.